<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5167425</article-id><article-id pub-id-type="pmid">27992547</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0168732</article-id><article-id pub-id-type="publisher-id">PONE-D-16-38621</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Dose Prediction Methods</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Evolutionary Biology</subject><subj-group><subject>Population Genetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Population Genetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Genetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Evolutionary Biology</subject><subj-group><subject>Population Genetics</subject><subj-group><subject>Genetic Polymorphism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Population Genetics</subject><subj-group><subject>Genetic Polymorphism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Genetics</subject><subj-group><subject>Genetic Polymorphism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical compounds</subject><subj-group><subject>Organic compounds</subject><subj-group><subject>Vitamins</subject><subj-group><subject>B vitamins</subject><subj-group><subject>Vitamin K</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic chemistry</subject><subj-group><subject>Organic compounds</subject><subj-group><subject>Vitamins</subject><subj-group><subject>B vitamins</subject><subj-group><subject>Vitamin K</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Database and Informatics Methods</subject><subj-group><subject>Database Searching</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Population groupings</subject><subj-group><subject>Ethnicities</subject><subj-group><subject>African Americans</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genetic Loci</subject><subj-group><subject>Alleles</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Applied Mathematics</subject><subj-group><subject>Algorithms</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Simulation and Modeling</subject><subj-group><subject>Algorithms</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review</article-title><alt-title alt-title-type="running-head">Warfarin Pharmacogenetics in MENA Region</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bader</surname><given-names>Loulia Akram</given-names></name><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1594-1199</contrib-id><name><surname>Elewa</surname><given-names>Hazem</given-names></name><xref ref-type="aff" rid="aff001"/><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><addr-line>College of Pharmacy, Qatar University, Doha, Qatar</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Novelli</surname><given-names>Giuseppe</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Universita degli Studi di Roma Tor Vergata, ITALY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> LB HE.</p></list-item><list-item><p><bold>Data curation:</bold> LB HE.</p></list-item><list-item><p><bold>Formal analysis:</bold> LB HE.</p></list-item><list-item><p><bold>Funding acquisition:</bold> LB HE.</p></list-item><list-item><p><bold>Investigation:</bold> LB HE.</p></list-item><list-item><p><bold>Methodology:</bold> LB HE.</p></list-item><list-item><p><bold>Project administration:</bold> LB HE.</p></list-item><list-item><p><bold>Supervision:</bold> HE.</p></list-item><list-item><p><bold>Validation:</bold> LB HE.</p></list-item><list-item><p><bold>Visualization:</bold> LB HE.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> LB.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> LB HE.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>hazem.elewa@qu.edu.qa</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>12</issue><elocation-id>e0168732</elocation-id><history><date date-type="received"><day>27</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>5</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Bader, Elewa</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Bader, Elewa</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0168732.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Warfarin is the most commonly used oral anticoagulant for the treatment and prevention of thromboembolic disorders. Pharmacogenomics studies have shown that variants in <italic>CYP2C9</italic> and <italic>VKORC1</italic> genes are strongly and consistently associated with warfarin dose variability. Although different populations from the Middle East and North Africa (MENA) region may share the same ancestry, it is still unclear how they compare in the genetic and non-genetic factors affecting their warfarin dosing.</p></sec><sec id="sec002"><title>Objective</title><p>To explore the prevalence of <italic>CYP2C9</italic> and <italic>VKORC1</italic> variants in MENA, and the effect of these variants along with other non-genetic factors in predicting warfarin dose.</p></sec><sec id="sec003"><title>Methods</title><p>In this systematic review, we included observational cross sectional and cohort studies that enrolled patients on stable warfarin dose and had the genetics and non-genetics factors associated with mean warfarin dose as the primary outcome. We searched PubMed, Medline, Scopus, PharmGKB, PHGKB, Google scholar and reference lists of relevant reviews.</p></sec><sec id="sec004"><title>Results</title><p>We identified 17 studies in eight different populations: Iranian, Israeli, Egyptian, Lebanese, Omani, Kuwaiti, Sudanese and Turkish. Most common genetic variant in all populations was the <italic>VKORC1 (-1639G&#x0003e;A)</italic>, with a minor allele frequency ranging from 30% in Egyptians and up to 52% and 56% in Lebanese and Iranian, respectively. Variants in the <italic>CYP2C9</italic> were less common, with the highest MAF for <italic>CYP2C9*2</italic> among Iranians (27%). Variants in the <italic>VKORC1</italic> and <italic>CYP2C9</italic> were the most significant predictors of warfarin dose in all populations. Along with other genetic and non-genetic factors, they explained up to 63% of the dose variability in Omani and Israeli patients.</p></sec><sec id="sec005"><title>Conclusion</title><p>Variants of <italic>VKORC1</italic> and <italic>CYP2C9</italic> are the strongest predictors of warfarin dose variability among the different populations from MENA. Although many of those populations share the same ancestry and are similar in their warfarin dose predictors, a population specific dosing algorithm is needed for the prospective estimation of warfarin dose.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>Qatar University (QA) Internal student grant</institution></funding-source><award-id>QUST-CPH-SPR-15/16-8</award-id><principal-award-recipient><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1594-1199</contrib-id><name><surname>Elewa</surname><given-names>Hazem</given-names></name></principal-award-recipient></award-group><funding-statement>This research was funded by the student grant provided by College of Pharmacy, Qatar University (QUST-CPH-SPR-15/16-8, <ext-link ext-link-type="uri" xlink:href="http://www.qu.edu.qa/offices/research/academic/internal-fund.php">http://www.qu.edu.qa/offices/research/academic/internal-fund.php</ext-link>), to HE. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are freely available and are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are freely available and are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec006"><title>Introduction</title><p>Warfarin is the most widely used oral anticoagulant for the treatment and prevention of thromboembolic manifestations associated with atrial fibrillation, prosthetic heart valves, orthopedic surgery, and history of vascular thrombosis [<xref rid="pone.0168732.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0168732.ref002" ref-type="bibr">2</xref>]. For example, in the United States alone, around 30 million warfarin prescriptions are dispensed annually, and in the year of 2010, total direct expenditures on warfarin were estimated to be around $600 million [<xref rid="pone.0168732.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0168732.ref003" ref-type="bibr">3</xref>]. Warfarin is a vitamin K antagonist that mediates its anticoagulant effect through preventing the activation of several vitamin K dependent coagulation factors including:- factors II, VII, IX, and X [<xref rid="pone.0168732.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0168732.ref005" ref-type="bibr">5</xref>]. Because of its narrow therapeutic index and wide interpatient variability, warfarin therapy requires close monitoring and repeated dose adjustments to achieve and maintain therapeutic anticoagulation effect [<xref rid="pone.0168732.ref006" ref-type="bibr">6</xref>&#x02013;<xref rid="pone.0168732.ref008" ref-type="bibr">8</xref>]. Studies have repeatedly shown that genetic and non-genetic factors are contributing to the warfarin dose variability [<xref rid="pone.0168732.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0168732.ref011" ref-type="bibr">11</xref>]. The most important genes consistently affecting warfarin dose among different populations are the <italic>CYP2C9</italic>- a gene coding for cytochrome P450 2C9 enzyme which metabolizes the more potent <italic>S</italic> enantiomer of warfarin, and <italic>VKORC1</italic>- a gene coding for the vitamin K epoxide reductase which is an enzyme inhibited by warfarin [<xref rid="pone.0168732.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0168732.ref010" ref-type="bibr">10</xref>]. Mutations in the gene coding for the CYP4F2, a metabolizing enzyme for vitamin K, have also been shown to contribute to warfarin dose variability but to a lesser extent, and its effect was not consistent among all populations [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0168732.ref013" ref-type="bibr">13</xref>]. The Clarification of Optimal Anticoagulation through Genetics (COAG) and the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) were the largest randomized controlled trials designed to assess the utility of genotype-guided dosing [<xref rid="pone.0168732.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0168732.ref015" ref-type="bibr">15</xref>]. Despite the negative results from the COAG trial indicating no benefit of genetic-guided dosing, compared to clinical dosing, it showed that the percent time in therapeutic range (PTTR) was significantly lower in blacks in the genetic-guided arm compared to the clinical dosing arm [<xref rid="pone.0168732.ref014" ref-type="bibr">14</xref>]. This is probably due to the fact that blacks may have other less-common genetic variants affecting their warfarin dose that were not well-represented in the genetic-algorithm used in the COAG trial [<xref rid="pone.0168732.ref016" ref-type="bibr">16</xref>]. The EU-PACT study on the other hand, compared pharmacogenetics-based doing versus fixed-dose strategy and was performed in a predominantly white population from Europe [<xref rid="pone.0168732.ref015" ref-type="bibr">15</xref>]. In this study, mean PTTR at 3 months was significantly higher in the genotype-guided group than in the control group [<xref rid="pone.0168732.ref015" ref-type="bibr">15</xref>].</p><p>Due to its strategic location and its resources, the Middle East and North Africa (MENA) region was always left at conflict, with different civilizations migrating in and out of its countries. That in turn have put populations of MENA through genetic admixture and racial mixing, creating heavily admixed populations with Asian, Caucasian, Arab and African ancestries. Numerous studies in different countries of MENA have been conducted to estimate the frequencies of the genetic mutations associated with warfarin dosing and its ability along with other non-genetic factors to predict warfarin dose. However, it is still not very clear to what extent the results of these studies are comparable and whether all or some of these results should be pooled together to come-up with a more accurate algorithm. As such, we felt that a summary of the evidence on warfarin pharmacogenetics in this region is needed in-order to identify the gaps and provide future directions. Our goal was to systematically review studies from the MENA region that estimate the impact of genetic and non-genetic factors on warfarin dose requirements.</p><p>Study objectives: to systematically review all observational studies that have explored the effect of both genetic and non-genetic factors on warfarin dose variability in the MENA region, estimate the prevalence of the studied genetic variations that are associated with warfarin dose variability, and compare the performance of different genetic-based algorithms in warfarin dose prediction.</p></sec><sec sec-type="materials|methods" id="sec007"><title>Methods</title><sec id="sec008"><title>Search Strategy</title><p>A systematic comprehensive search for observational studies was applied with no date or language restrictions. The search started on February 2016 and was completed by the end of March 2016.</p><sec id="sec009"><title>Database search</title><p>PubMed, Scopus, MedLine, PharmGKB (Pharmacogenomics Knowledge Base), and PHGKB (Public Health Genomics Knowledge Base) were searched using different terms with the appropriate Booleans. Below is an example of the search terms and Boolean used to search PubMed. Similar terms were used to search other databases, for Scopus and MedLine results were refined by country.</p><list list-type="bullet"><list-item><p>Combination #1: &#x0201c;warfarin&#x0201d; AND &#x0201c;dose prediction&#x0201d; AND &#x0201c;genetic polymorphism&#x0201d; (In title and abstract).</p></list-item><list-item><p>Combination #2: &#x0201c;warfarin&#x0201d; AND &#x0201c;dosing&#x0201d; AND &#x0201c;genetic mutations&#x0201d; (In title and abstract).</p></list-item><list-item><p>Combination #3: &#x0201c;warfarin&#x0201d; AND &#x0201c;genotype guided&#x0201d; AND &#x0201c;algorithm&#x0201d; (ALL fields).</p></list-item><list-item><p>Combination #4: &#x0201c;warfarin&#x0201d; AND &#x0201c;polymorphism&#x0201d; AND &#x0201c;dose prediction&#x0201d;.</p></list-item><list-item><p>Combination #5: #1 OR #2 OR #3 OR #4.</p></list-item></list></sec><sec id="sec010"><title>Other resources</title><p>For grey literature, Google Scholar was searched without any language or date limits. Moreover, reference list of all kind of relevant review articles retrieved during our search, were hand searched to identify any potential study.</p></sec></sec><sec id="sec011"><title>Study Types</title><p>Observational cross sectional or cohort studies were included. Randomized controlled studies, case control, case series, and qualitative studies were excluded from this review.</p></sec><sec id="sec012"><title>Participants</title><p>Adult patients from MENA region, who have been on warfarin for a sufficient amount of time to have a stable dose and their International Normalized Ratio (INR) within the therapeutic range.</p></sec><sec id="sec013"><title>Outcome Measure</title><p>Included studies were required to have mean warfarin dose as their primary outcome and to have estimated the variability in the dose explained by genetic and non-genetic factors.</p></sec><sec id="sec014"><title>Eligibility Criteria</title><p>Studies were considered eligible for this review if they have studied populations of the MENA region, have explored the effect of both genetic and non-genetic factors on warfarin dose, and have developed a dosing model.</p></sec><sec id="sec015"><title>Study Selection</title><p>Potentially relevant studies were screened first by title and abstract to exclude any irrelevant studies. Then studies were screened by text to exclude any study that does not apply the inclusion criteria. Both former steps were carried by two reviewers (HE and LB), independently. Whenever there was a disagreement, it was resolved by discussion.</p></sec><sec id="sec016"><title>Data Extraction and Management</title><p>Data were extracted with a pre-specified and piloted extraction tool that was prepared and reviewed by the authors. Abstracted data included: author and year of publication, population studied, sample size, genetic and non-genetic factors explored, mean warfarin dose, mean INR, and main findings.</p></sec><sec id="sec017"><title>Quality Assessment</title><p>Quality assessment tool for observational cohort and cross sectional studies, adopted from the NIH, National Heart, Lung, and Blood Institute [<xref rid="pone.0168732.ref017" ref-type="bibr">17</xref>] was used to assess the quality of all included studies.</p></sec><sec id="sec018"><title>Data Synthesis</title><p>All extracted data were summarized and presented descriptively.</p></sec></sec><sec sec-type="results" id="sec019"><title>Results</title><sec id="sec020"><title>Study Selection</title><p>A total of 17 studies were included in this review, including 8 different populations. <xref ref-type="fig" rid="pone.0168732.g001">Fig 1</xref> shows a flow chart of the included studies. Out of 32 studies screened for eligibility, 12 studies were excluded for not targeting patients from the MENA region [<xref rid="pone.0168732.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0168732.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0168732.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0168732.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0168732.ref026" ref-type="bibr">26</xref>] and 3 studies were excluded [<xref rid="pone.0168732.ref027" ref-type="bibr">27</xref>&#x02013;<xref rid="pone.0168732.ref029" ref-type="bibr">29</xref>] as they did not develop a dosing model. We identified studies from 8 different countries including: Egypt, Iran, Lebanon, Turkey, Sudan, Oman, Kuwait, and two studies in occupied Palestine on Israeli population. Characteristics of all studies are shown in <xref rid="pone.0168732.t001" ref-type="table">Table 1</xref>.</p><fig id="pone.0168732.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0168732.g001</object-id><label>Fig 1</label><caption><title>PRISMA Flow Chart of Included Studies.</title></caption><graphic xlink:href="pone.0168732.g001"/></fig><table-wrap id="pone.0168732.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0168732.t001</object-id><label>Table 1</label><caption><title>study Characteristics.</title></caption><alternatives><graphic id="pone.0168732.t001g" xlink:href="pone.0168732.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Population</th><th align="left" rowspan="1" colspan="1">Sample size</th><th align="left" rowspan="1" colspan="1">Genetic factors explored</th><th align="left" rowspan="1" colspan="1">Non-genetic factors explored</th><th align="left" rowspan="1" colspan="1">Mean warfarin dose</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Shahin et. al. 2011, 2013</italic> [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0168732.ref030" ref-type="bibr">30</xref>]</td><td align="left" rowspan="1" colspan="1">Egyptians</td><td align="left" rowspan="1" colspan="1">207</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic>(*2, *3, *4, *5, *8),<italic>VKORC1</italic> (3673G&#x0003e;A, Asp36Tyr), <italic>APOE</italic>, <italic>CYP4F2</italic>(Val433Met), <italic>CALU</italic></td><td align="left" rowspan="1" colspan="1">Sex, age, BSA, use of aspirin, indication for warfarin, concomitant disease &#x00026; smoking status</td><td align="left" rowspan="1" colspan="1">36.8 &#x000b1; 17.9 mg/wk</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Bazan et. al. 2014</italic> [<xref rid="pone.0168732.ref031" ref-type="bibr">31</xref>]</td><td align="left" rowspan="1" colspan="1">Egyptians</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic>(*2, *3), <italic>VKORC1</italic></td><td align="left" rowspan="1" colspan="1">Age &#x00026; smoking status</td><td align="left" rowspan="1" colspan="1">7.3 &#x000b1; 5.2 (1&#x02013;30) mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Ghozlan et. al. 2015</italic> [<xref rid="pone.0168732.ref032" ref-type="bibr">32</xref>]</td><td align="left" rowspan="1" colspan="1">Egyptians with ACS</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic>, <italic>VKORC1</italic></td><td align="left" rowspan="1" colspan="1">Age &#x00026; height</td><td align="left" rowspan="1" colspan="1">4.8 &#x000b1; 1.96 (2&#x02013;10) mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Issac et. al. 2014 &#x00026; Ekladious et. al. 2013</italic> [<xref rid="pone.0168732.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0168732.ref034" ref-type="bibr">34</xref>]</td><td align="left" rowspan="1" colspan="1">Egyptian</td><td align="left" rowspan="1" colspan="1">84 (50 for model, 34 for validation)</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic>(1075A&#x0003e;C), <italic>VKORC1</italic>(1173C&#x0003e;T), <italic>R1</italic>, (C3435T), <italic>EPHX1</italic>(H139R), <italic>PZ</italic>(A-13G)</td><td align="left" rowspan="1" colspan="1">Age &#x00026; gender</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Namazi et. al. 2010</italic> [<xref rid="pone.0168732.ref035" ref-type="bibr">35</xref>]</td><td align="left" rowspan="1" colspan="1">Iranian</td><td align="left" rowspan="1" colspan="1">100 total (100 CYP2C9, 99 CYP2C19, 81 VKORC1) 55 for the model</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic> (*2, *3), <italic>VKORC1</italic> (-1639G&#x0003e;A), <italic>CYP2C19</italic> (*2, *3)</td><td align="left" rowspan="1" colspan="1">Gender, age, BSA, weight &#x00026; height</td><td align="left" rowspan="1" colspan="1">7.3 &#x000b1; 5.2 (1&#x02013;30) mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Loebstein et. al. 2005</italic> [<xref rid="pone.0168732.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0168732.ref037" ref-type="bibr">37</xref>]</td><td align="left" rowspan="1" colspan="1">Israeli</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1"><italic>GGCX</italic>, <italic>CALU</italic>, <italic>VKORC1</italic>, <italic>EPHX1</italic>, <italic>CYP2C9</italic> (*2, *3)</td><td align="left" rowspan="1" colspan="1">Age, weight, concurrent medication &#x00026; total vit.K plasma concentration</td><td align="left" rowspan="1" colspan="1">5.7 &#x000b1; 3.3 (1.1&#x02013;20) mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Alrashid et. al. 2016</italic> [<xref rid="pone.0168732.ref038" ref-type="bibr">38</xref>]</td><td align="left" rowspan="1" colspan="1">Kuwaiti</td><td align="left" rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic>, <italic>VKORC1</italic></td><td align="left" rowspan="1" colspan="1">Sex &#x00026; BMI, age were adjusted for in the model but not included as predictors</td><td align="left" rowspan="1" colspan="1">4.7 &#x000b1; 2.7 mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Esmerian et. al. 2011</italic> [<xref rid="pone.0168732.ref039" ref-type="bibr">39</xref>]</td><td align="left" rowspan="1" colspan="1">Lebanese</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9 (*2</italic>, <italic>*3)</italic>, <italic>VKORC1</italic> (-1639G&#x0003e;A, 1173 C&#x0003e;T)</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">31 &#x000b1; 14 mg/wk</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Pathare et. al. 2012</italic> [<xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>]</td><td align="left" rowspan="1" colspan="1">Omani</td><td align="left" rowspan="1" colspan="1">212 (142 in the model derivation cohort, 70 for validation)</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic> (*2, *3), <italic>CYP4F2 *3</italic>, <italic>VKORC1</italic> (3673G&#x0003e;A, 5808T&#x0003e;G, 6009C&#x0003e;T, 6484C&#x0003e;T, 9041G&#x0003e;A)</td><td align="left" rowspan="1" colspan="1">Simvastatin, amiodarone, hypertension, diabetes, atrial fibrillation, deep vein thrombosis, mechanical valve, age, weight &#x00026; gender</td><td align="left" rowspan="1" colspan="1">4.75 (3&#x02013;5.5) mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Shrif et. al. 2011</italic> [<xref rid="pone.0168732.ref041" ref-type="bibr">41</xref>]</td><td align="left" rowspan="1" colspan="1">Sudanese</td><td align="left" rowspan="1" colspan="1">203 patients 180 healthy volunteers</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic> (*2, *3, *5, *6, *8, *9, *11), <italic>VKORC1</italic> (20 tagSNPs)</td><td align="left" rowspan="1" colspan="1">Body weight, concurrent medication, target INR, body surface area, height, age, indication for warfarin treatment &#x00026; gender</td><td align="left" rowspan="1" colspan="1">5.58 &#x000b1; 2.48 (1.5&#x02013;22.5) mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x000d6;zer et. al. 2013</italic> [<xref rid="pone.0168732.ref042" ref-type="bibr">42</xref>]</td><td align="left" rowspan="1" colspan="1">Turkish</td><td align="left" rowspan="1" colspan="1">107</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic> (*1,*2), <italic>VKORC1</italic>(-1639G&#x0003e;A, 1173C&#x0003e;T), <italic>CYP4F2</italic>, <italic>EPHX1</italic></td><td align="left" rowspan="1" colspan="1">Age, height, weight, No. of cigarettes &#x00026; daily consumed tea and green vegetables</td><td align="left" rowspan="1" colspan="1">5.16 &#x000b1; 1.95 (1.43&#x02013;10) mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Ozgon et. al. 2008</italic> [<xref rid="pone.0168732.ref043" ref-type="bibr">43</xref>]</td><td align="left" rowspan="1" colspan="1">Turkish</td><td align="left" rowspan="1" colspan="1">205</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic> (*2,*3,*4,*5), <italic>VKORC1</italic> (-1639G&#x0003e;A)</td><td align="left" rowspan="1" colspan="1">Age &#x00026; non-indication of VT</td><td align="left" rowspan="1" colspan="1">34.2 &#x000b1; 16.78 (6.25&#x02013;125) mg/wk</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Yildirim et. al. 2014</italic> [<xref rid="pone.0168732.ref044" ref-type="bibr">44</xref>]</td><td align="left" rowspan="1" colspan="1">Turkish</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic> (*2,*3), <italic>VKORC1</italic>(-1639G&#x0003e;A), <italic>factor VII</italic> (-401G&#x0003e;T)</td><td align="left" rowspan="1" colspan="1">Age, BMI &#x00026; INR</td><td align="left" rowspan="1" colspan="1">4.07 &#x000b1; 1.6(1.13&#x02013;7.86) mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Ozer et. al. 2010</italic> [<xref rid="pone.0168732.ref045" ref-type="bibr">45</xref>]</td><td align="left" rowspan="1" colspan="1">Turkish</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1"><italic>CYP2C9</italic>(*2,*3), <italic>VKORC1</italic>(-1639G&#x0003e;A)</td><td align="left" rowspan="1" colspan="1">Age &#x00026; BSA</td><td align="left" rowspan="1" colspan="1">4.11 (1.16&#x02013;9.33) mg/day</td></tr></tbody></table></alternatives></table-wrap><p>After assessing for quality, most studies were found to be ranging from fair to good quality. However, the study by Alrashid et al [<xref rid="pone.0168732.ref038" ref-type="bibr">38</xref>] was considered of poor quality as there was no reporting of the r<sup>2</sup> value for the dosing model. The sample-size used in some of the studies was less than 100, which is relatively low and may have affected the power of their conclusions [<xref rid="pone.0168732.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0168732.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0168732.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0168732.ref039" ref-type="bibr">39</xref>]. Testing for the Hardy-Weinberg equilibrium was reported in all studies except those by Yildirim et al [<xref rid="pone.0168732.ref044" ref-type="bibr">44</xref>] and Ghozlan et al [<xref rid="pone.0168732.ref032" ref-type="bibr">32</xref>].</p><p>Targeted populations were required to be on stable warfarin dose as part of the inclusion criteria. Due to the variability in the definition of stable warfarin dose among studies, we reported the different definitions used by authors of each included study (<xref rid="pone.0168732.t002" ref-type="table">Table 2</xref>). Overall, having an INR within therapeutic range for three consecutive visits while on the same warfarin dose was considered &#x0201c;stable warfarin dose&#x0201d; description by almost all studies.</p><table-wrap id="pone.0168732.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0168732.t002</object-id><label>Table 2</label><caption><title>Stable Warfarin Dose Definition Variation Among Studies.</title></caption><alternatives><graphic id="pone.0168732.t002g" xlink:href="pone.0168732.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Studies</th><th align="left" rowspan="1" colspan="1">Definition</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Shrif et. al. 2013</italic> [<xref rid="pone.0168732.ref041" ref-type="bibr">41</xref>]</td><td align="left" rowspan="1" colspan="1">Mean of the daily warfarin doses at which INR measurements were within target therapeutic levels for three consecutive clinic visits over more than 3 months</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Namazi et. al. 2010</italic> [<xref rid="pone.0168732.ref035" ref-type="bibr">35</xref>]</td><td align="left" rowspan="1" colspan="1">Warfarin dose that was constant for &#x02265; 3 consecutive visits over a minimum period of 3 months with INR value variation &#x02264; 15%</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Esmerian et. al. 2011</italic> [<xref rid="pone.0168732.ref039" ref-type="bibr">39</xref>]</td><td align="left" rowspan="1" colspan="1">Therapy for at least 2 months, same weekly dose of warfarin over the past 3 INR examinations, patients considered adequately coagulated if the INR value at recruitment fell within a range of 1.7&#x02013;4</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Pathare et. al. 2012</italic> [<xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>]</td><td align="left" rowspan="1" colspan="1">A patient was considered to have a stable INR when his/her INR was between 2 and 3 on at least 3 consecutive assessments, 3 months after initiating the therapy</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Alrashid et. al. 2016</italic> [<xref rid="pone.0168732.ref038" ref-type="bibr">38</xref>]</td><td align="left" rowspan="1" colspan="1">Patients were defined as those whose warfarin dose requirement has remained constant for at least three consecutive clinic visits, at which point the INR was within the therapeutic range</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Bazan et. al. 2014</italic> [<xref rid="pone.0168732.ref031" ref-type="bibr">31</xref>]</td><td align="left" rowspan="1" colspan="1">Patients having a stable warfarin dose requirement for at least 3 consecutive times with dose titration to an INR target range of 2&#x02013;3.5</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Shahin et. al. 2011, 2013</italic> [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>]</td><td align="left" rowspan="1" colspan="1">A dose that did not vary by more than 10% between clinic visit, for three consecutive visits, occurring over a minimum time-period of 2 months</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Ghozlan et. al. 2015</italic> [<xref rid="pone.0168732.ref032" ref-type="bibr">32</xref>]</td><td align="left" rowspan="1" colspan="1">Steady-state dose that leads to stable anticoagulation levels in three consecutive clinic visits for which the INR measurements are within the range of 2&#x02013;3</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Yildirim et. el. 2014</italic> [<xref rid="pone.0168732.ref044" ref-type="bibr">44</xref>]</td><td align="left" rowspan="1" colspan="1">Not clearly defined</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>&#x000d6;zer et. al. 2013</italic> [<xref rid="pone.0168732.ref042" ref-type="bibr">42</xref>]</td><td align="left" rowspan="1" colspan="1">Patients were included if they had been on therapy for &#x0003e; 4 months and their last three INR measurements were within therapeutic range for the same mean daily dose</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Ozgon et. al. 2008</italic> [<xref rid="pone.0168732.ref043" ref-type="bibr">43</xref>]</td><td align="left" rowspan="1" colspan="1">Patients were included if they had been on therapy &#x0003e;2 months and their last three INR measurements were considered stable by their doctors, whether or not they correspond to their target INR</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Loebstein et. al. 2005</italic> [<xref rid="pone.0168732.ref037" ref-type="bibr">37</xref>]</td><td align="left" rowspan="1" colspan="1">Having therapeutic INR over 4 consecutive visit and receiving the same daily dose of warfarin before sample collection on index visit</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Issac et. al. 2014 &#x00026; Ekladious et. al. 2013</italic> [<xref rid="pone.0168732.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0168732.ref034" ref-type="bibr">34</xref>]</td><td align="left" rowspan="1" colspan="1">Having at least three consecutive INRs in the therapeutic (2&#x02013;3) range for the same daily maintenance dose after at least 3 months of therapy</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Ozer et. al. 2010</italic> [<xref rid="pone.0168732.ref045" ref-type="bibr">45</xref>]</td><td align="left" rowspan="1" colspan="1">Three consecutive clinic visits for which INR measurements were within therapeutic range for the same daily dose</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec021"><title>Prevalence of the studied genetic variants</title><p>In-order to estimate the prevalence of different genetic variants we reported the minor allele frequency (MAF) of these variants. For the most common genetic variants in <italic>VKORC1</italic> and <italic>CYP2C9</italic>, MAF&#x02019;s are presented in <xref rid="pone.0168732.t003" ref-type="table">Table 3</xref>. Variants in the <italic>VKORC1</italic> gene had the highest frequencies among all populations followed by the *2 variant of <italic>CYP2C9</italic> gene and *3, with *2 being relatively higher in most of the populations.</p><table-wrap id="pone.0168732.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0168732.t003</object-id><label>Table 3</label><caption><title>Minor Allele Frequency (MAF) of Most Common Genetic Variants.</title></caption><alternatives><graphic id="pone.0168732.t003g" xlink:href="pone.0168732.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Population</th><th align="center" rowspan="1" colspan="1">Gene</th><th align="center" rowspan="1" colspan="1"><italic>VKORC1</italic></th><th align="center" colspan="2" rowspan="1"><italic>CYP2C9</italic></th></tr><tr><th align="center" rowspan="1" colspan="1">Variant</th><th align="center" rowspan="1" colspan="1">-1639 G&#x0003e;A (rs9923231)<xref ref-type="table-fn" rid="t003fn001">*</xref></th><th align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t003fn001">*</xref>2(rs179853)</th><th align="center" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t003fn001">*</xref>3(rs1057910)</th></tr></thead><tbody><tr><td align="justify" colspan="2" rowspan="1">Egyptians [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0168732.ref030" ref-type="bibr">30</xref>]</td><td align="center" rowspan="1" colspan="1">46.2%</td><td align="center" rowspan="1" colspan="1">11.7</td><td align="center" rowspan="1" colspan="1">9.2%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Egyptians [<xref rid="pone.0168732.ref034" ref-type="bibr">34</xref>]</td><td align="center" rowspan="1" colspan="1">72.05%</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">10.7%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Egyptians [<xref rid="pone.0168732.ref031" ref-type="bibr">31</xref>]</td><td align="center" rowspan="1" colspan="1">51%</td><td align="center" rowspan="1" colspan="1">7%</td><td align="center" rowspan="1" colspan="1">9.6%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Egyptians [<xref rid="pone.0168732.ref032" ref-type="bibr">32</xref>]</td><td align="center" rowspan="1" colspan="1">30%</td><td align="center" rowspan="1" colspan="1">8%</td><td align="center" rowspan="1" colspan="1">4.3%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Iranian [<xref rid="pone.0168732.ref035" ref-type="bibr">35</xref>]</td><td align="center" rowspan="1" colspan="1">56%</td><td align="center" rowspan="1" colspan="1">27%</td><td align="center" rowspan="1" colspan="1">9%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Israeli [<xref rid="pone.0168732.ref036" ref-type="bibr">36</xref>]</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">12.5%</td><td align="center" rowspan="1" colspan="1">11%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Kuwaiti [<xref rid="pone.0168732.ref038" ref-type="bibr">38</xref>]</td><td align="center" rowspan="1" colspan="1">40%</td><td align="center" rowspan="1" colspan="1">14%</td><td align="center" rowspan="1" colspan="1">5%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Lebanese [<xref rid="pone.0168732.ref039" ref-type="bibr">39</xref>]</td><td align="center" rowspan="1" colspan="1">52%</td><td align="center" rowspan="1" colspan="1">15%</td><td align="center" rowspan="1" colspan="1">7%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Omani [<xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>]</td><td align="center" rowspan="1" colspan="1">35%</td><td align="center" rowspan="1" colspan="1">6%</td><td align="center" rowspan="1" colspan="1">6%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Sudanese [<xref rid="pone.0168732.ref041" ref-type="bibr">41</xref>]</td><td align="center" rowspan="1" colspan="1">37%</td><td align="center" rowspan="1" colspan="1">5%</td><td align="center" rowspan="1" colspan="1">0%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Turkish [<xref rid="pone.0168732.ref043" ref-type="bibr">43</xref>]</td><td align="center" rowspan="1" colspan="1">50%</td><td align="center" rowspan="1" colspan="1">13%</td><td align="center" rowspan="1" colspan="1">10%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Turkish [<xref rid="pone.0168732.ref042" ref-type="bibr">42</xref>]</td><td align="center" rowspan="1" colspan="1">49%</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">N/A</td></tr><tr><td align="justify" colspan="2" rowspan="1">Turkish [<xref rid="pone.0168732.ref045" ref-type="bibr">45</xref>]</td><td align="center" rowspan="1" colspan="1">40%</td><td align="center" rowspan="1" colspan="1">13%</td><td align="center" rowspan="1" colspan="1">15%</td></tr><tr><td align="justify" colspan="2" rowspan="1">Turkish [<xref rid="pone.0168732.ref044" ref-type="bibr">44</xref>]</td><td align="center" rowspan="1" colspan="1">51%</td><td align="center" rowspan="1" colspan="1">17%</td><td align="center" rowspan="1" colspan="1">27%</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>* This rs ID refers to <italic>VKORC1</italic> (-1639G&#x0003e;A) and <italic>VKORC1</italic>(3673G&#x0003e;A)</p></fn></table-wrap-foot></table-wrap><p>Other less common genetic variants have been explored in Egyptians, Israeli, Omani, and Turkish populations. These include variants in the following genes: <italic>CYP4F2</italic>, <italic>EPHX1</italic>, <italic>GGCX1</italic>, <italic>MDR1</italic>, <italic>factor VII</italic>, <italic>APOE</italic>, <italic>CALU</italic> and <italic>PZ</italic>. The MAF for the <italic>CYP4F2</italic> (rs2108622) was 40% among Turkish [<xref rid="pone.0168732.ref042" ref-type="bibr">42</xref>], 30% in Omani [<xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>] and 42% in Egyptians [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>]. The <italic>EPHX1</italic> encodes for a putative subunit of the vitamin K epoxide reductase complex called: microsomal epoxide hydrolase 1 [<xref rid="pone.0168732.ref010" ref-type="bibr">10</xref>]. The MAF of <italic>EPHX1</italic> (rs2292566) was 16% and 26.19% in Turkish and Egyptians, respectively [<xref rid="pone.0168732.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0168732.ref042" ref-type="bibr">42</xref>], while another variant the (rs1051740) was 25% in Israeli [<xref rid="pone.0168732.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0168732.ref037" ref-type="bibr">37</xref>]. The multidrug resistance gene (<italic>MDR1</italic> C3435T) and <italic>Protein Z</italic> A-13G were only studied in Egyptians and their MAF were 42.86% and 0%, respectively [<xref rid="pone.0168732.ref033" ref-type="bibr">33</xref>]. Other gene variants that are associated with warfarin dose variability are the <italic>APOE</italic> and <italic>CALU</italic> [<xref rid="pone.0168732.ref010" ref-type="bibr">10</xref>]. The rs429358 and rs7412 variants of the <italic>APOE</italic> gene had a MAF of 6.7% and 7.4%, in Egyptians, respectively [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>]. On the other hand, the rs339097 variant of the <italic>CALU</italic> gene was less common in Egyptians than the <italic>APOE</italic> variants with a MAF of 2.3% [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>]. Other rare genetic variants that have been explored are the <italic>Factor VII</italic> (-401G&#x0003e;A) which had a MAF of 35% in Turkish [<xref rid="pone.0168732.ref042" ref-type="bibr">42</xref>], and the <italic>GGCX</italic> (rs699664) which had a MAF of 29.5% in Israeli [<xref rid="pone.0168732.ref036" ref-type="bibr">36</xref>].</p></sec><sec id="sec022"><title>Significant Predictors of Warfarin Dose</title><p>Using univariate and multivariate linear regression, authors of all studies were able to identify the most significant predictors of warfarin dose and the most significant dosing model which explained the highest percent of the dose variability. <xref rid="pone.0168732.t004" ref-type="table">Table 4</xref> shows the significant predictors in the different populations and to what extent were they able to predict warfarin dose.</p><table-wrap id="pone.0168732.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0168732.t004</object-id><label>Table 4</label><caption><title>Most Significant Predictors and % Variability Explained.</title></caption><alternatives><graphic id="pone.0168732.t004g" xlink:href="pone.0168732.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Population</th><th align="left" rowspan="1" colspan="1">Significant Genetic Predictors</th><th align="left" rowspan="1" colspan="1">Significant Non-Genetic Predictors</th><th align="left" rowspan="1" colspan="1">Variability explained by the model</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Egyptians</bold> [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0168732.ref030" ref-type="bibr">30</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>V<italic>KORC1</italic> (-1639G&#x0003e;A) &#x00026; (Asp36Tyr)</p></list-item><list-item><p><italic>CYP2C9</italic>(*2,*3,*4,*5,*8)</p></list-item><list-item><p>APOE&#x003b5;2</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Age</p></list-item><list-item><p>Pulmonary embolism</p></list-item><list-item><p>Smoking status</p></list-item></list></td><td align="left" rowspan="1" colspan="1">36.5%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Egyptians</bold> [<xref rid="pone.0168732.ref032" ref-type="bibr">32</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>VKORC1(-1639G&#x0003e;A)</p></list-item><list-item><p>CYP2C9 *2 &#x00026; *3</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Age</p></list-item><list-item><p>Height</p></list-item></list></td><td align="left" rowspan="1" colspan="1">30.6%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Egyptians</bold> [<xref rid="pone.0168732.ref031" ref-type="bibr">31</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>VKORC1 (-1639G&#x0003e;A)</p></list-item><list-item><p>CYP2C9*3</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Age</p></list-item><list-item><p>Smoking status</p></list-item></list></td><td align="left" rowspan="1" colspan="1">43.4%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Egyptians</bold> [<xref rid="pone.0168732.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0168732.ref034" ref-type="bibr">34</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic>(1173 C&#x0003e;T)</p></list-item><list-item><p><italic>MDR1</italic> (p = 0.055)</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Age</p></list-item></list></td><td align="left" rowspan="1" colspan="1">20.9%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Iranian</bold> [<xref rid="pone.0168732.ref035" ref-type="bibr">35</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic> (-1639G&#x0003e;A)</p></list-item><list-item><p><italic>CYP2C9</italic> *2 &#x00026; *3</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Age</p></list-item><list-item><p>Sex</p></list-item><list-item><p>Height</p></list-item></list></td><td align="left" rowspan="1" colspan="1">41.3%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Israeli</bold> [<xref rid="pone.0168732.ref037" ref-type="bibr">37</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic> (1542G&#x0003e;C)</p></list-item><list-item><p><italic>CYP2C9</italic> *2 &#x00026; *3</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Age</p></list-item><list-item><p>Weight</p></list-item></list></td><td align="left" rowspan="1" colspan="1">63%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Kuwaiti</bold> [<xref rid="pone.0168732.ref038" ref-type="bibr">38</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic> (-1639G&#x0003e;A)</p></list-item><list-item><p><italic>CYP2C9</italic> *2 &#x00026; *3</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Age</p></list-item><list-item><p>Body Mass Index</p></list-item></list></td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Lebanese</bold> [<xref rid="pone.0168732.ref039" ref-type="bibr">39</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic> (-1639G&#x0003e;A)</p></list-item><list-item><p><italic>CYP2C9</italic> *2 &#x00026; *3</p></list-item></list></td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">33.9%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Omani</bold> [<xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic> 3673(GA &#x00026; AA)</p></list-item><list-item><p><italic>CYP2C9</italic> (*2/*3, *3/*3)</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Atrial fibrillation</p></list-item></list></td><td align="left" rowspan="1" colspan="1">63%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Sudanese</bold> [<xref rid="pone.0168732.ref041" ref-type="bibr">41</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic>(rs8050894,rs7199949, rs7294),</p></list-item><list-item><p><italic>CYP2C9</italic> (*2,*5,*6,*11)</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Concurrent medication</p></list-item><list-item><p>Indication for warfarin</p></list-item></list></td><td align="left" rowspan="1" colspan="1">36.75</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Turkish</bold> [<xref rid="pone.0168732.ref043" ref-type="bibr">43</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic> (3673 G&#x0003e;A)</p></list-item><list-item><p><italic>CYP2C9</italic> *2, *3, &#x00026; *4</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Age</p></list-item><list-item><p>Non-indication of VTE</p></list-item></list></td><td align="left" rowspan="1" colspan="1">43%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Turkish</bold> [<xref rid="pone.0168732.ref045" ref-type="bibr">45</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic>(-1639 G&#x0003e;A)</p></list-item><list-item><p><italic>CYP2C9</italic> *2 &#x00026; *3</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Age</p></list-item><list-item><p>Body surface area</p></list-item></list></td><td align="left" rowspan="1" colspan="1">60.4%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Turkish</bold> [<xref rid="pone.0168732.ref042" ref-type="bibr">42</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic>(-1639G&#x0003e;A)</p></list-item><list-item><p><italic>CYP2C9</italic> *2 &#x00026;*3</p></list-item><list-item><p><italic>CYP4F2</italic> (rs2108622)</p></list-item></list></td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Age</p></list-item></list></td><td align="left" rowspan="1" colspan="1">39.3%</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Turkish</bold> [<xref rid="pone.0168732.ref044" ref-type="bibr">44</xref>]</td><td align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic>VKORC1</italic> (-1639G&#x0003e;A)</p></list-item></list></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18.2%</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec sec-type="conclusions" id="sec023"><title>Discussion</title><sec id="sec024"><title>Summary of Evidence</title><p>The term MENA refers to countries from Morocco to Iran and down to Sudan. Studies of maternally inherited mitochondrial DNA have suggested that all modern populations, including those of MENA [<xref rid="pone.0168732.ref046" ref-type="bibr">46</xref>&#x02013;<xref rid="pone.0168732.ref048" ref-type="bibr">48</xref>], have originated through a single wave from Sub Saharan Africa and populated other parts of the world [<xref rid="pone.0168732.ref049" ref-type="bibr">49</xref>]. Later-on, several historical events took place and facilitated genetic migration like the early Islamic conquests, the Ottoman Empire expansion and the continuous migrations in and out of the Arabian Peninsula and Europe. Other examples include the silk and spice road, which used to connect China with Europe through the Middle East [<xref rid="pone.0168732.ref050" ref-type="bibr">50</xref>]. Countries like Egypt and Oman, their strategic crossroad position between Africa and Eurasia have left them with high intrapopulation diversity [<xref rid="pone.0168732.ref046" ref-type="bibr">46</xref>]. On the other hand, other countries like Qatar and Yemen have the highest rates of consanguinity, 44.7% and 54%, respectively, leaving them with less genetic variability [<xref rid="pone.0168732.ref051" ref-type="bibr">51</xref>]. All of the aforementioned reasons have made these countries of particular interest in genetic studies.</p><p>Pharmacogenetics studies have shown that variants of <italic>VKORC1</italic> and <italic>CYP2C9</italic> are strongly associated with warfarin dose. <italic>VKORC1</italic>(-1639G&#x0003e;A) alone can explain up to 40% of the dose variation in some populations [<xref rid="pone.0168732.ref052" ref-type="bibr">52</xref>]. Along with these genetic predictors, other genetic factors and non-genetic factors such as age, weight, gender, race, ethnicity, concurrent medication, and comorbidities can boost the preemptive estimation of warfarin dosing to more than 50% [<xref rid="pone.0168732.ref010" ref-type="bibr">10</xref>].</p><p>The fact that <italic>VKORC1</italic> variants are the most significant predictors of warfarin dose followed by those of <italic>CYP2C9</italic>, was consistent across all studies included in this systematic review. However, the frequency of these genetic variations and the extent of their effect on dose variability varied from population to another. Similarities were seen between Sudanese and African Americans in that <italic>CYP2C9</italic>*5, *6, and *11 were better predictors of warfarin dose than the *2 and *3 variants [<xref rid="pone.0168732.ref053" ref-type="bibr">53</xref>]. Moreover, the variability explained by variants of <italic>VKORC1</italic> (rs9934438, rs9923231, rs8050894) were comparable to those of African Americans [<xref rid="pone.0168732.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0168732.ref053" ref-type="bibr">53</xref>]. <italic>CYP2C9</italic>*8 (rs9332094) is another rare variant that affects around 12% of African Americans and has been associated with reduced <italic>S</italic>-warfarin clearance [<xref rid="pone.0168732.ref054" ref-type="bibr">54</xref>]. This SNP was only investigated in two populations of MENA; Egyptians and Sudanese [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0168732.ref041" ref-type="bibr">41</xref>]. Despite some of the similarities found between these two populations and African Americans, the <italic>CYP2C9*8</italic> did not shown any significant association with warfarin dose requirements in Egyptians and Sudanese as it did in African Americans. This might be in part due the fact that this variant was not very common in these populations, it showed a MAF of 0.008 and 0.01 in Egyptians and Sudanese, respectively [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0168732.ref041" ref-type="bibr">41</xref>]. On the other hand, the frequencies of <italic>CYP2C9</italic> *2 and *3 and <italic>VKORC1</italic> (3673G&#x0003e;A) reported in Turkish [<xref rid="pone.0168732.ref043" ref-type="bibr">43</xref>] were closer to Caucasians than to Asians and African Americans [<xref rid="pone.0168732.ref001" ref-type="bibr">1</xref>].</p><p>Variants of the <italic>VKORC1</italic> gene were the most prevalent among all populations. Great discrepancy was seen in the frequency of the <italic>VKORC1</italic> in Egyptians, it ranged from 30% in the study be Ghozlan et. al and up to 72% in the study by Ekladious et. al. [<xref rid="pone.0168732.ref032" ref-type="bibr">32</xref>]. Such discrepancy could be in part due to the small sample sizes used in the different studies concerning the Egyptian population, in particular the studies by Ghozlan, Ekladious, and Bazan and their colleagues [<xref rid="pone.0168732.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0168732.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0168732.ref034" ref-type="bibr">34</xref>]. Moreover, the Egyptian population is a heavily admixed population with different ethnic origins [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>] which may have led to different frequencies depending on the ethnicity of the studied population. However, none of these studies have reported the different ethnic origins of their studied population and whether it was a contributing factor or not. Carriers of the -1639G&#x0003e;A variant required lower warfarin dose compared to the wild type in all studies. Shrif and colleagues were able to identify four different SNPs downstream from the <italic>VKORC1</italic> gene (rs7199949, rs11865038, rs11864839, and rs750952). These SNPs were found to be located in newly identified gene which is only 2 kb downstream from the <italic>VKORC1</italic> gene in the same reverse strand named: <italic>POL3S</italic> (polyserase 3S) [<xref rid="pone.0168732.ref041" ref-type="bibr">41</xref>]. Amino acid sequences of the POL3S are highly conserved among humans, chimpanzees, dogs, cows, and mice [<xref rid="pone.0168732.ref055" ref-type="bibr">55</xref>]. While function of the encoded protein is still unknown in-vivo, it has shown to degrade the alpha chain of fibrinogen as well as pro-urokinase type plasminogen in vitro, indicating its potential role in the coagulation process [<xref rid="pone.0168732.ref055" ref-type="bibr">55</xref>]. Out of the identified SNPs in the <italic>POL3S</italic>, rs7199949 (p.Pro406Ala) proved to be a significant predictor of warfarin dose and its addition to the regression model explained 7% of the variability [<xref rid="pone.0168732.ref041" ref-type="bibr">41</xref>].</p><p>Variants in the <italic>CYP2C9</italic> were less common than those of the <italic>VKORC1</italic> in all populations with the *2 variant being slightly more common than the *3 variant in majority of cases. The *2 variant was highest among Iranian (27%) [<xref rid="pone.0168732.ref035" ref-type="bibr">35</xref>], while the *3 variant was highest among Turkish (27%) and it was not detected in Sudanese [<xref rid="pone.0168732.ref041" ref-type="bibr">41</xref>, <xref rid="pone.0168732.ref044" ref-type="bibr">44</xref>]. MAF of *2 and *3 were closely similar among Egyptians, Israeli, and Turkish [<xref rid="pone.0168732.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0168732.ref036" ref-type="bibr">36</xref>, <xref rid="pone.0168732.ref043" ref-type="bibr">43</xref>]. Both *2 and *3 variants were associated with lower warfarin dose requirements in all populations.</p><p>The <italic>VKORC1</italic> (-1639G&#x0003e;A) variant was the most significant predictor of warfarin dose in all population. This variant alone was able to explain 45% of the dose variability in Omani [<xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>]. The <italic>VKORC1</italic> Asp36Tyr was significantly associated with higher warfarin doses in Egyptians and when added to Shahin et al. dosing model it further explained the variability by only 2% [<xref rid="pone.0168732.ref030" ref-type="bibr">30</xref>].</p><p><italic>CYP4F2</italic> is the gene coding for the cytochrome P450 4F2 enzyme, which is a vitamin K oxidase. The V433M allele is associated with reduced metabolism of vitamin K1 and higher warfarin doses [<xref rid="pone.0168732.ref056" ref-type="bibr">56</xref>]. Caldwell et al. has shown that <italic>CYP4F2</italic> V433M (rs2108622) variant has an impact on warfarin dose and that carriers of at least one minor allele required 4&#x02013;12% higher doses than those with homozygous wild type genotype [<xref rid="pone.0168732.ref057" ref-type="bibr">57</xref>]. Only 3 studies in three different populations of MENA -Egyptian, Omani, and Turkish- have investigated the association between warfarin dose and that gene variant. These studies have shown no significant association between <italic>CYP4F2</italic> gene variant and warfarin dose in Egyptians neither in Omani, despite its high frequency [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>]. A significant association between <italic>CYP4F2</italic> gene variant and warfarin dose was among Turkish by &#x000d6;zer et. al [<xref rid="pone.0168732.ref042" ref-type="bibr">42</xref>]. Furthermore, Turkish carriers of the variant allele required higher warfarin doses than those with the wildtype. The <italic>APOE</italic> gene encodes for an apolipoprotein that is involved in the hepatic clearance of vitamin K [<xref rid="pone.0168732.ref010" ref-type="bibr">10</xref>]. In the Egyptian cohort studied by Shahin. et. al., carriers of the <italic>APOE &#x003b5;2</italic> gene variant required lower warfarin dose compared to the wild type [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>]. Moreover, that variant explained 2.53% of the dose variability. No association was found between <italic>MDR1</italic> C3435T, <italic>EPHX1</italic> H139R, <italic>GGCX</italic> and <italic>protein Z</italic> A-13G gene variations and warfarin dose in populations of MENA. However, when combined, these genetic variants were able to explain 3% of the dose variability in Egyptians [<xref rid="pone.0168732.ref033" ref-type="bibr">33</xref>]. Calumenin (CALU) is a regulator of vitamin K epoxide reductase (VKOR) as identified in studies of warfarin resistance rat and it have been linked to warfarin sensitivity [<xref rid="pone.0168732.ref058" ref-type="bibr">58</xref>]. Shahin et al. was able to confirm the association of <italic>CALU</italic> rs339097 gene polymorphism with higher doses of warfarin, however, when added to the regression model it failed to show any significance [<xref rid="pone.0168732.ref012" ref-type="bibr">12</xref>]. The authors reported that failing to show significance may have been due to lack of power, since only nine variant carriers were found in their cohort. In African Americans, it was shown, that for every <italic>CALU</italic> rs339097 variant allele warfarin dose increases by almost 11% [<xref rid="pone.0168732.ref058" ref-type="bibr">58</xref>]. Factor VII is a vitamin K dependent factor, <italic>factor VII</italic> -401G&#x0003e;T variant was able to predict only 2.2% of warfarin dose variability among Turkish, even though it had an MAF of 35% [<xref rid="pone.0168732.ref044" ref-type="bibr">44</xref>]. Carriers of the minor allele required lower warfarin dose as opposed to the carriers of the major allele [<xref rid="pone.0168732.ref044" ref-type="bibr">44</xref>].</p><p>After developing their dosing algorithm, Pathare et al. compared the performance of their algorithm with that of the International Warfarin Pharmacogenetics Consortium (IWPC) in predicting warfarin dose in their Omani cohort [<xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>]. The IWPC algorithm was able to explain only 33.6% of the variability, while Pathare et al. algorithm explained 63% of the variability [<xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>]. Moreover, warfarin dose predicted by the IWPC algorithm was 13% higher than the patients&#x02019; actual dose [<xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>]. Even though the IWPC algorithm has been developed and validated using data from different racial groups including Asians, Blacks, and Whites across four different countries, and even though the Omani population comes from Asian, African and Caucasian ancestries, the IWPC algorithm did not perform well in the Omani population [<xref rid="pone.0168732.ref040" ref-type="bibr">40</xref>]. Such variation in the algorithm performance could be owed to the fluctuation in racial definitions, clinical variations, social/lifestyle contexts, population migration and historical perspectives [<xref rid="pone.0168732.ref059" ref-type="bibr">59</xref>]. Such observation highlights the need for dosing algorithm that are more population-tailored.</p><p>Beside the genetic variants other clinical and demographic variables were shown to be significantly associated with warfarin dose. Age, weight, gender, body mass index and body surface area were the most significant predictors of warfarin dose and added up to the variability explained.</p></sec></sec><sec id="sec025"><title>Limitations</title><p>Some of the limitations of this review were having only two reviewers carrying the whole process independently which may have led us to overlook some important findings or observations. Another limitation is that we only considered mean warfarin dose as our primary outcome, while other outcomes like Time to Therapeutic Range (TTR) and risk of bleeding might be predicted by genetic factors. Furthermore, SNPs like the <italic>GGCX</italic>, <italic>Factor VII</italic>, <italic>CALU</italic>, <italic>APOE</italic>, <italic>MDR1</italic>, <italic>EPHX1</italic>, and <italic>PZ</italic> were investigated in limited number of studies, which made it unfeasible for us to compare their effect on warfarin dose between different populations of MENA.</p><sec id="sec026"><title>Conclusions and Future Directions</title><p><italic>VKORC1 &#x00026; CYP2C9</italic> were the most useful variants in predicting warfarin dose. Despite the shared significant predictors in all dosing models, their performance still varied largely between populations. As such, micro-geographically defined population specific dosing algorithms are needed. Warfarin pharmacogenetics have been explored in limited number of populations in MENA region. Thus, more pharmacogenetics studies on other populations are needed to further explain the impact of genetic factors on warfarin dose in the region. Future clinical utility and cost effectiveness studies will confirm if warfarin genetic dosing strategy should replace clinical dosing.</p></sec></sec></body><back><ref-list><title>References</title><ref id="pone.0168732.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>JL</given-names></name>, <name><surname>Horne</surname><given-names>BD</given-names></name>, <name><surname>Stevens</surname><given-names>SM</given-names></name>, <name><surname>Grove</surname><given-names>AS</given-names></name>, <name><surname>Barton</surname><given-names>S</given-names></name>, <name><surname>Nicholas</surname><given-names>ZP</given-names></name>, <etal>et al</etal>
<article-title>Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation</article-title>. <source>Circulation</source>. <year>2007</year>
<month>11</month>
<day>27</day>;<volume>116</volume>(<issue>22</issue>):<fpage>2563</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.737312</pub-id>
<?supplied-pmid 17989110?><pub-id pub-id-type="pmid">17989110</pub-id></mixed-citation></ref><ref id="pone.0168732.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Kirley</surname><given-names>K</given-names></name>, <name><surname>Qato</surname><given-names>DM</given-names></name>, <name><surname>Kornfield</surname><given-names>R</given-names></name>, <name><surname>Stafford</surname><given-names>RS</given-names></name>, <name><surname>Alexander</surname><given-names>GC</given-names></name>. <article-title>National trends in oral anticoagulant use in the United States, 2007 to 2011</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2012</year>
<month>9</month>
<day>1</day>;<volume>5</volume>(<issue>5</issue>):<fpage>615</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.112.967299</pub-id>
<?supplied-pmid 22949490?><pub-id pub-id-type="pmid">22949490</pub-id></mixed-citation></ref><ref id="pone.0168732.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Wysowski</surname><given-names>DK</given-names></name>, <name><surname>Nourjah</surname><given-names>P</given-names></name>, <name><surname>Swartz</surname><given-names>L</given-names></name>. <article-title>Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action</article-title>. <source>Archives of internal medicine</source>. <year>2007</year>
<month>7</month>
<day>9</day>;<volume>167</volume>(<issue>13</issue>):<fpage>1414</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.167.13.1414</pub-id>
<?supplied-pmid 17620536?><pub-id pub-id-type="pmid">17620536</pub-id></mixed-citation></ref><ref id="pone.0168732.ref004"><label>4</label><mixed-citation publication-type="book"><name><surname>Thomas</surname><given-names>DD</given-names></name>. In: <name><surname>Thomas</surname><given-names>DD</given-names></name>, editor. <source>Hemostasis and Thrombosis</source>: <publisher-name>Springer International Publishing Switzerland</publisher-name>
<year>2015</year>; 2014. p. <fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0168732.ref005"><label>5</label><mixed-citation publication-type="book">In: <name><surname>Offermanns</surname><given-names>S</given-names></name>, <name><surname>Rosenthal</surname><given-names>W</given-names></name>, editors. <source>Encyclopedia of Molecular Pharmacology</source>. <edition>2nd ed</edition>
<publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2008</year> p. <fpage>948</fpage>&#x02013;<lpage>50</lpage>.</mixed-citation></ref><ref id="pone.0168732.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Landefeld</surname><given-names>CS</given-names></name>, <name><surname>Beyth</surname><given-names>RJ</given-names></name>. <article-title>Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention</article-title>. <source>Am J Med</source>. <year>1993</year>
<month>9</month>;<volume>95</volume>(<issue>3</issue>):<fpage>315</fpage>&#x02013;<lpage>28</lpage>. <?supplied-pmid 8368229?><pub-id pub-id-type="pmid">8368229</pub-id></mixed-citation></ref><ref id="pone.0168732.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Klein</surname><given-names>TE</given-names></name>, <name><surname>Altman</surname><given-names>RB</given-names></name>, <name><surname>Eriksson</surname><given-names>N</given-names></name>, <name><surname>Gage</surname><given-names>BF</given-names></name>, <name><surname>Kimmel</surname><given-names>SE</given-names></name>, <name><surname>Lee</surname><given-names>MT</given-names></name>, <etal>et al</etal>
<article-title>Estimation of the warfarin dose with clinical and pharmacogenetic data</article-title>. <source>N Engl J Med</source>. <year>2009</year>
<month>2</month>
<day>19</day>;<volume>360</volume>(<issue>8</issue>):<fpage>753</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0809329</pub-id>
<?supplied-pmid 19228618?><pub-id pub-id-type="pmid">19228618</pub-id></mixed-citation></ref><ref id="pone.0168732.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>JA</given-names></name>. <article-title>Warfarin: an old drug but still interesting</article-title>. <source>Pharmacotherapy</source>. <year>2008</year>
<month>9</month>;<volume>28</volume>(<issue>9</issue>):<fpage>1081</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1592/phco.28.9.1081</pub-id>
<?supplied-pmid 18752378?><pub-id pub-id-type="pmid">18752378</pub-id></mixed-citation></ref><ref id="pone.0168732.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Kamali</surname><given-names>F</given-names></name>, <name><surname>Khan</surname><given-names>TI</given-names></name>, <name><surname>King</surname><given-names>BP</given-names></name>, <name><surname>Frearson</surname><given-names>R</given-names></name>, <name><surname>Kesteven</surname><given-names>P</given-names></name>, <name><surname>Wood</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin</article-title>. <source>Clin Pharmacol Ther</source>. <year>2004</year>
<month>3</month>;<volume>75</volume>(<issue>3</issue>):<fpage>204</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.clpt.2003.10.001</pub-id>
<?supplied-pmid 15001972?><pub-id pub-id-type="pmid">15001972</pub-id></mixed-citation></ref><ref id="pone.0168732.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Wadelius</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>LY</given-names></name>, <name><surname>Eriksson</surname><given-names>N</given-names></name>, <name><surname>Bumpstead</surname><given-names>S</given-names></name>, <name><surname>Ghori</surname><given-names>J</given-names></name>, <name><surname>Wadelius</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Association of warfarin dose with genes involved in its action and metabolism</article-title>. <source>Hum Genet</source>. <year>2007</year>
<month>3</month>;<volume>121</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-006-0260-8</pub-id>
<?supplied-pmid 17048007?><pub-id pub-id-type="pmid">17048007</pub-id></mixed-citation></ref><ref id="pone.0168732.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>HY</given-names></name>, <name><surname>Chen</surname><given-names>JJ</given-names></name>, <name><surname>Lee</surname><given-names>MT</given-names></name>, <name><surname>Wung</surname><given-names>JC</given-names></name>, <name><surname>Chen</surname><given-names>YF</given-names></name>, <name><surname>Charng</surname><given-names>MJ</given-names></name>, <etal>et al</etal>
<article-title>A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity</article-title>. <source>Hum Mol Genet</source>. <year>2005</year>
<month>7</month>
<day>1</day>;<volume>14</volume>(<issue>13</issue>):<fpage>1745</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddi180</pub-id>
<?supplied-pmid 15888487?><pub-id pub-id-type="pmid">15888487</pub-id></mixed-citation></ref><ref id="pone.0168732.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Shahin</surname><given-names>MH</given-names></name>, <name><surname>Khalifa</surname><given-names>SI</given-names></name>, <name><surname>Gong</surname><given-names>Y</given-names></name>, <name><surname>Hammad</surname><given-names>LN</given-names></name>, <name><surname>Sallam</surname><given-names>MT</given-names></name>, <name><surname>El Shafey</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients</article-title>. <source>Pharmacogenet Genomics</source>. <year>2011</year>
<month>3</month>;<volume>21</volume>(<issue>3</issue>):<fpage>130</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/FPC.0b013e3283436b86</pub-id>
<?supplied-pmid 21228733?><pub-id pub-id-type="pmid">21228733</pub-id></mixed-citation></ref><ref id="pone.0168732.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Takeuchi</surname><given-names>F</given-names></name>, <name><surname>McGinnis</surname><given-names>R</given-names></name>, <name><surname>Bourgeois</surname><given-names>S</given-names></name>, <name><surname>Barnes</surname><given-names>C</given-names></name>, <name><surname>Eriksson</surname><given-names>N</given-names></name>, <name><surname>Soranzo</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose</article-title>. <source>PLoS Genet</source>. <year>2009</year>
<month>3</month>;<volume>5</volume>(<issue>3</issue>):<fpage>e1000433</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1000433</pub-id>
<?supplied-pmid 19300499?><pub-id pub-id-type="pmid">19300499</pub-id></mixed-citation></ref><ref id="pone.0168732.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Kimmel</surname><given-names>SE</given-names></name>, <name><surname>French</surname><given-names>B</given-names></name>, <name><surname>Kasner</surname><given-names>SE</given-names></name>, <name><surname>Johnson</surname><given-names>JA</given-names></name>, <name><surname>Anderson</surname><given-names>JL</given-names></name>, <name><surname>Gage</surname><given-names>BF</given-names></name>, <etal>et al</etal>
<article-title>A pharmacogenetic versus a clinical algorithm for warfarin dosing</article-title>. <source>N Engl J Med</source>. <year>2013</year>
<month>12</month>
<day>12</day>;<volume>369</volume>(<issue>24</issue>):<fpage>2283</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1310669</pub-id>
<?supplied-pmid 24251361?><pub-id pub-id-type="pmid">24251361</pub-id></mixed-citation></ref><ref id="pone.0168732.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Pirmohamed</surname><given-names>M</given-names></name>, <name><surname>Burnside</surname><given-names>G</given-names></name>, <name><surname>Eriksson</surname><given-names>N</given-names></name>, <name><surname>Jorgensen</surname><given-names>AL</given-names></name>, <name><surname>Toh</surname><given-names>CH</given-names></name>, <name><surname>Nicholson</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>A randomized trial of genotype-guided dosing of warfarin</article-title>. <source>N Engl J Med</source>. <year>2013</year>
<month>12</month>
<day>12</day>;<volume>369</volume>(<issue>24</issue>):<fpage>2294</fpage>&#x02013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1311386</pub-id>
<?supplied-pmid 24251363?><pub-id pub-id-type="pmid">24251363</pub-id></mixed-citation></ref><ref id="pone.0168732.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>JA</given-names></name>, <name><surname>Cavallari</surname><given-names>LH</given-names></name>. <article-title>Warfarin pharmacogenetics</article-title>. <source>Trends Cardiovasc Med</source>. <year>2015</year>
<month>1</month>;<volume>25</volume>(<issue>1</issue>):<fpage>33</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcm.2014.09.001</pub-id>
<?supplied-pmid 25282448?><pub-id pub-id-type="pmid">25282448</pub-id></mixed-citation></ref><ref id="pone.0168732.ref017"><label>17</label><mixed-citation publication-type="other">Health NIo. Quality Assessment Tool for Observatioanl Cohort and Cross-Sectional Studies. In: Natioanl Heart L, and Blood Institute, editor.2014.</mixed-citation></ref><ref id="pone.0168732.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Carlquist</surname><given-names>JF</given-names></name>, <name><surname>Horne</surname><given-names>BD</given-names></name>, <name><surname>Mower</surname><given-names>C</given-names></name>, <name><surname>Park</surname><given-names>J</given-names></name>, <name><surname>Huntinghouse</surname><given-names>J</given-names></name>, <name><surname>McKinney</surname><given-names>JT</given-names></name>, <etal>et al</etal>
<article-title>An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction</article-title>. <source>J Thromb Thrombolysis</source>. <year>2010</year>
<month>10</month>;<volume>30</volume>(<issue>3</issue>):<fpage>358</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1007/s11239-010-0467-3</pub-id>
<?supplied-pmid 20499136?><pub-id pub-id-type="pmid">20499136</pub-id></mixed-citation></ref><ref id="pone.0168732.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Caldwell</surname><given-names>MD</given-names></name>, <name><surname>Berg</surname><given-names>RL</given-names></name>, <name><surname>Zhang</surname><given-names>KQ</given-names></name>, <name><surname>Glurich</surname><given-names>I</given-names></name>, <name><surname>Schmelzer</surname><given-names>JR</given-names></name>, <name><surname>Yale</surname><given-names>SH</given-names></name>, <etal>et al</etal>
<article-title>Evaluation of genetic factors for warfarin dose prediction</article-title>. <source>Clin Med Res</source>. <year>2007</year>
<month>3</month>;<volume>5</volume>(<issue>1</issue>):<fpage>8</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.3121/cmr.2007.724</pub-id>
<?supplied-pmid 17456829?><pub-id pub-id-type="pmid">17456829</pub-id></mixed-citation></ref><ref id="pone.0168732.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Carlquist</surname><given-names>JF</given-names></name>, <name><surname>Horne</surname><given-names>BD</given-names></name>, <name><surname>Muhlestein</surname><given-names>JB</given-names></name>, <name><surname>Lappe</surname><given-names>DL</given-names></name>, <name><surname>Whiting</surname><given-names>BM</given-names></name>, <name><surname>Kolek</surname><given-names>MJ</given-names></name>, <etal>et al</etal>
<article-title>Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study</article-title>. <source>J Thromb Thrombolysis</source>. <year>2006</year>
<month>12</month>;<volume>22</volume>(<issue>3</issue>):<fpage>191</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s11239-006-9030-7</pub-id>
<?supplied-pmid 17111199?><pub-id pub-id-type="pmid">17111199</pub-id></mixed-citation></ref><ref id="pone.0168732.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Gage</surname><given-names>BF</given-names></name>, <name><surname>Eby</surname><given-names>C</given-names></name>, <name><surname>Milligan</surname><given-names>PE</given-names></name>, <name><surname>Banet</surname><given-names>GA</given-names></name>, <name><surname>Duncan</surname><given-names>JR</given-names></name>, <name><surname>McLeod</surname><given-names>HL</given-names></name>. <article-title>Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin</article-title>. <source>Thromb Haemost</source>. <year>2004</year>
<month>1</month>;<volume>91</volume>(<issue>1</issue>):<fpage>87</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1160/TH03-06-0379</pub-id>
<?supplied-pmid 14691573?><pub-id pub-id-type="pmid">14691573</pub-id></mixed-citation></ref><ref id="pone.0168732.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>SW</given-names></name>, <name><surname>Xiang</surname><given-names>DK</given-names></name>, <name><surname>Wu</surname><given-names>HL</given-names></name>, <name><surname>Chen</surname><given-names>BL</given-names></name>, <name><surname>An</surname><given-names>BQ</given-names></name>, <name><surname>Li</surname><given-names>GF</given-names></name>. [<article-title>Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose</article-title>]. <source>Zhonghua Yi Xue Yi Chuan Xue Za Zhi</source>. <year>2011</year>
<month>12</month>;<volume>28</volume>(<issue>6</issue>):<fpage>661</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.3760/cma.j.issn.1003-9406.2011.06.014</pub-id>
<?supplied-pmid 22161100?><pub-id pub-id-type="pmid">22161100</pub-id></mixed-citation></ref><ref id="pone.0168732.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>Y</given-names></name>, <name><surname>Shennan</surname><given-names>M</given-names></name>, <name><surname>Reynolds</surname><given-names>KK</given-names></name>, <name><surname>Johnson</surname><given-names>NA</given-names></name>, <name><surname>Herrnberger</surname><given-names>MR</given-names></name>, <name><surname>Valdes</surname><given-names>R</given-names><suffix>Jr.</suffix></name>, <etal>et al</etal>
<article-title>Estimation of warfarin maintenance dose based on VKORC1 (-1639 G&#x0003e;A) and CYP2C9 genotypes</article-title>. <source>Clin Chem</source>. <year>2007</year>
<month>7</month>;<volume>53</volume>(<issue>7</issue>):<fpage>1199</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1373/clinchem.2006.078139</pub-id>
<?supplied-pmid 17510308?><pub-id pub-id-type="pmid">17510308</pub-id></mixed-citation></ref><ref id="pone.0168732.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Wadelius</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>LY</given-names></name>, <name><surname>Downes</surname><given-names>K</given-names></name>, <name><surname>Ghori</surname><given-names>J</given-names></name>, <name><surname>Hunt</surname><given-names>S</given-names></name>, <name><surname>Eriksson</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Common VKORC1 and GGCX polymorphisms associated with warfarin dose</article-title>. <source>Pharmacogenomics J</source>. <year>2005</year>;<volume>5</volume>(<issue>4</issue>):<fpage>262</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1038/sj.tpj.6500313</pub-id>
<?supplied-pmid 15883587?><pub-id pub-id-type="pmid">15883587</pub-id></mixed-citation></ref><ref id="pone.0168732.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Santos</surname><given-names>PC</given-names></name>, <name><surname>Dinardo</surname><given-names>CL</given-names></name>, <name><surname>Schettert</surname><given-names>IT</given-names></name>, <name><surname>Soares</surname><given-names>RA</given-names></name>, <name><surname>Kawabata-Yoshihara</surname><given-names>L</given-names></name>, <name><surname>Bensenor</surname><given-names>IM</given-names></name>, <etal>et al</etal>
<article-title>CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2012</year>
<month>4</month>;<volume>69</volume>(<issue>4</issue>):<fpage>789</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-012-1404-5</pub-id>
<?supplied-pmid 22990331?><pub-id pub-id-type="pmid">22990331</pub-id></mixed-citation></ref><ref id="pone.0168732.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Aquilante</surname><given-names>CL</given-names></name>, <name><surname>Langaee</surname><given-names>TY</given-names></name>, <name><surname>Lopez</surname><given-names>LM</given-names></name>, <name><surname>Yarandi</surname><given-names>HN</given-names></name>, <name><surname>Tromberg</surname><given-names>JS</given-names></name>, <name><surname>Mohuczy</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements</article-title>. <source>Clin Pharmacol Ther</source>. <year>2006</year>
<month>4</month>;<volume>79</volume>(<issue>4</issue>):<fpage>291</fpage>&#x02013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1016/j.clpt.2005.11.011</pub-id>
<?supplied-pmid 16580898?><pub-id pub-id-type="pmid">16580898</pub-id></mixed-citation></ref><ref id="pone.0168732.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Pathar</surname><given-names>A</given-names></name>, <name><surname>Alkindi</surname><given-names>S</given-names></name>, <name><surname>Al Zadjali</surname><given-names>S</given-names></name>, <name><surname>Misquith</surname><given-names>R</given-names></name>, <name><surname>Wasim</surname><given-names>F</given-names></name>, <name><surname>Berbar</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Combined effect of CYP2C9 and VKORC1 polymorphisms on warfarin maintance dose in Omani patients</article-title>. <source>Open Journal of Genetics</source>; <year>2012</year>.</mixed-citation></ref><ref id="pone.0168732.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Yildirim</surname><given-names>R</given-names></name>, <name><surname>Gundogdu</surname><given-names>M</given-names></name>, <name><surname>Kurnaz</surname><given-names>F</given-names></name>, <name><surname>Yildirim</surname><given-names>A</given-names></name>, <name><surname>Aksoy</surname><given-names>H</given-names></name>, <name><surname>Erdem</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>CYP2C9 gene polymorphisms and warfarin dose requirement: a single-center experience in Turkey</article-title>. <source>Turkish Journal of Medical Sciences</source>. <year>2012</year>
<month>12</month>;<volume>42</volume>(<issue>6</issue>):<fpage>981</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0168732.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Yildirim</surname><given-names>R</given-names></name>, <name><surname>Yildirim</surname><given-names>A</given-names></name>, <name><surname>Laloglu</surname><given-names>E</given-names></name>, <name><surname>Cadirci</surname><given-names>K</given-names></name>, <name><surname>Erdem</surname><given-names>F</given-names></name>, <name><surname>Kiki</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Effect of VKORC1-1639 G &#x0003e; A polymorphism on warfarin response in east of Turkey</article-title>. <source>Turkish Journal of Biochemistry-Turk Biyokimya Dergisi</source>. 2015 <year>2015</year>;<volume>40</volume>(<issue>4</issue>):<fpage>271</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="pone.0168732.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Shahin</surname><given-names>MH</given-names></name>, <name><surname>Cavallari</surname><given-names>LH</given-names></name>, <name><surname>Perera</surname><given-names>MA</given-names></name>, <name><surname>Khalifa</surname><given-names>SI</given-names></name>, <name><surname>Misher</surname><given-names>A</given-names></name>, <name><surname>Langaee</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians</article-title>. <source>Thromb Haemost</source>. <year>2013</year>
<month>6</month>;<volume>109</volume>(<issue>6</issue>):<fpage>1045</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1160/TH12-10-0789</pub-id>
<?supplied-pmid 23571513?><pub-id pub-id-type="pmid">23571513</pub-id></mixed-citation></ref><ref id="pone.0168732.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Bazan</surname><given-names>N</given-names></name>, <name><surname>Sabry</surname><given-names>N</given-names></name>, <name><surname>Rizk</surname><given-names>A</given-names></name>, <name><surname>Mokhtar</surname><given-names>S</given-names></name>, <name><surname>Badary</surname><given-names>O</given-names></name>. <article-title>Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism</article-title>. <source>Irish Journal of Medical Science</source>. <year>2014</year>;<volume>183</volume>(<issue>2</issue>):<fpage>161</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1007/s11845-013-0978-y</pub-id>
<?supplied-pmid 23800980?><pub-id pub-id-type="pmid">23800980</pub-id></mixed-citation></ref><ref id="pone.0168732.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Ghozlan</surname><given-names>MF</given-names></name>, <name><surname>Foad</surname><given-names>DA</given-names></name>, <name><surname>Darwish</surname><given-names>YW</given-names></name>, <name><surname>Saad</surname><given-names>AA</given-names></name>. <article-title>Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome</article-title>. <source>Blood Coagulation and Fibrinolysis</source>. [Article]. <year>2015</year>;<volume>26</volume>(<issue>5</issue>):<fpage>499</fpage>&#x02013;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1097/MBC.0000000000000272</pub-id>
<?supplied-pmid 25699611?><pub-id pub-id-type="pmid">25699611</pub-id></mixed-citation></ref><ref id="pone.0168732.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Issac</surname><given-names>MS</given-names></name>, <name><surname>El-Nahid</surname><given-names>MS</given-names></name>, <name><surname>Wissa</surname><given-names>MY</given-names></name>. <article-title>Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population</article-title>. <source>Mol Diagn Ther</source>. <year>2014</year>
<month>2</month>;<volume>18</volume>(<issue>1</issue>):<fpage>73</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s40291-013-0055-2</pub-id>
<?supplied-pmid 24092646?><pub-id pub-id-type="pmid">24092646</pub-id></mixed-citation></ref><ref id="pone.0168732.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Ekladious</surname><given-names>SM</given-names></name>, <name><surname>Issac</surname><given-names>MS</given-names></name>, <name><surname>El-Atty Sharaf</surname><given-names>SA</given-names></name>, <name><surname>Abou-Youssef</surname><given-names>HS</given-names></name>. <article-title>Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients</article-title>. <source>Mol Diagn Ther</source>. <year>2013</year>
<month>12</month>;<volume>17</volume>(<issue>6</issue>):<fpage>381</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1007/s40291-013-0046-3</pub-id>
<?supplied-pmid 23839801?><pub-id pub-id-type="pmid">23839801</pub-id></mixed-citation></ref><ref id="pone.0168732.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Namazi</surname><given-names>S</given-names></name>, <name><surname>Azarpira</surname><given-names>N</given-names></name>, <name><surname>Hendijani</surname><given-names>F</given-names></name>, <name><surname>Khorshid</surname><given-names>MB</given-names></name>, <name><surname>Vessal</surname><given-names>G</given-names></name>, <name><surname>Mehdipour</surname><given-names>AR</given-names></name>. <article-title>The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: A cross-sectional study in Iran</article-title>. <source>Clinical Therapeutics</source>. [Article]. <year>2010</year>;<volume>32</volume>(<issue>6</issue>):<fpage>1050</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinthera.2010.06.010</pub-id>
<?supplied-pmid 20637959?><pub-id pub-id-type="pmid">20637959</pub-id></mixed-citation></ref><ref id="pone.0168732.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Vecsler</surname><given-names>M</given-names></name>, <name><surname>Loebstein</surname><given-names>R</given-names></name>, <name><surname>Almog</surname><given-names>S</given-names></name>, <name><surname>Kurnik</surname><given-names>D</given-names></name>, <name><surname>Goldman</surname><given-names>B</given-names></name>, <name><surname>Halkin</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Combined genetic profiles of components and regulators of the vitamin K-dependent &#x003b3;-carboxylation system affect individual sensitivity to warfarin</article-title>. <source>Thrombosis and Haemostasis</source>. [Article]. <year>2006</year>;<volume>95</volume>(<issue>2</issue>):<fpage>205</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1160/TH05-06-0446</pub-id>
<?supplied-pmid 16493479?><pub-id pub-id-type="pmid">16493479</pub-id></mixed-citation></ref><ref id="pone.0168732.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Loebstein</surname><given-names>R</given-names></name>, <name><surname>Vecsler</surname><given-names>M</given-names></name>, <name><surname>Kurnik</surname><given-names>D</given-names></name>, <name><surname>Austerweil</surname><given-names>N</given-names></name>, <name><surname>Gak</surname><given-names>E</given-names></name>, <name><surname>Halkin</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9</article-title>. <source>Clinical Pharmacology and Therapeutics</source>. [Article]. <year>2005</year>;<volume>77</volume>(<issue>5</issue>):<fpage>365</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.clpt.2005.01.010</pub-id>
<?supplied-pmid 15900282?><pub-id pub-id-type="pmid">15900282</pub-id></mixed-citation></ref><ref id="pone.0168732.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Alrashid</surname><given-names>MH</given-names></name>, <name><surname>Al-Serri</surname><given-names>A</given-names></name>, <name><surname>Alshemmari</surname><given-names>SH</given-names></name>, <name><surname>Koshi</surname><given-names>P</given-names></name>, <name><surname>Al-Bustan</surname><given-names>SA</given-names></name>. <article-title>Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals</article-title>. <source>Mol Diagn Ther</source>. <year>2016</year>
<month>4</month>;<volume>20</volume>(<issue>2</issue>):<fpage>183</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1007/s40291-016-0190-7</pub-id>
<?supplied-pmid 26940072?><pub-id pub-id-type="pmid">26940072</pub-id></mixed-citation></ref><ref id="pone.0168732.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Esmerian</surname><given-names>MO</given-names></name>, <name><surname>Mitri</surname><given-names>Z</given-names></name>, <name><surname>Habbal</surname><given-names>MZ</given-names></name>, <name><surname>Geryess</surname><given-names>E</given-names></name>, <name><surname>Zaatari</surname><given-names>G</given-names></name>, <name><surname>Alam</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of lebanese people</article-title>. <source>Journal of Clinical Pharmacology</source>. [Article]. <year>2011</year>;<volume>51</volume>(<issue>10</issue>):<fpage>1418</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1177/0091270010382910</pub-id>
<?supplied-pmid 21148049?><pub-id pub-id-type="pmid">21148049</pub-id></mixed-citation></ref><ref id="pone.0168732.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Pathare</surname><given-names>A</given-names></name>, <name><surname>Al Khabori</surname><given-names>M</given-names></name>, <name><surname>Alkindi</surname><given-names>S</given-names></name>, <name><surname>Al Zadjali</surname><given-names>S</given-names></name>, <name><surname>Misquith</surname><given-names>R</given-names></name>, <name><surname>Khan</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients</article-title>. <source>Journal of Human Genetics</source>. <year>2012</year>
<month>10</month>;<volume>57</volume>(<issue>10</issue>):<fpage>665</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/jhg.2012.94</pub-id>
<?supplied-pmid 22854539?><pub-id pub-id-type="pmid">22854539</pub-id></mixed-citation></ref><ref id="pone.0168732.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Shrif</surname><given-names>NE</given-names></name>, <name><surname>Won</surname><given-names>HH</given-names></name>, <name><surname>Lee</surname><given-names>ST</given-names></name>, <name><surname>Park</surname><given-names>JH</given-names></name>, <name><surname>Kim</surname><given-names>KK</given-names></name>, <name><surname>Kim</surname><given-names>MJ</given-names></name>, <etal>et al</etal>
<article-title>Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2011</year>
<month>11</month>;<volume>67</volume>(<issue>11</issue>):<fpage>1119</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-011-1060-1</pub-id>
<?supplied-pmid 21590310?><pub-id pub-id-type="pmid">21590310</pub-id></mixed-citation></ref><ref id="pone.0168732.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>&#x000d6;zer</surname><given-names>M</given-names></name>, <name><surname>Demirci</surname><given-names>Y</given-names></name>, <name><surname>Hizel</surname><given-names>C</given-names></name>, <name><surname>Sarikaya</surname><given-names>S</given-names></name>, <name><surname>Karalti</surname><given-names>&#x00130;</given-names></name>, <name><surname>Kaspar</surname><given-names>&#x000c7;</given-names></name>, <etal>et al</etal>
<article-title>Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population</article-title>. <source>Basic Clin Pharmacol Toxicol</source>. <year>2013</year>
<month>3</month>;<volume>112</volume>(<issue>3</issue>):<fpage>209</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1111/bcpt.12024</pub-id>
<?supplied-pmid 23061746?><pub-id pub-id-type="pmid">23061746</pub-id></mixed-citation></ref><ref id="pone.0168732.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Oner Ozgon</surname><given-names>G</given-names></name>, <name><surname>Langaee</surname><given-names>TY</given-names></name>, <name><surname>Feng</surname><given-names>H</given-names></name>, <name><surname>Buyru</surname><given-names>N</given-names></name>, <name><surname>Ulutin</surname><given-names>T</given-names></name>, <name><surname>Hatemi</surname><given-names>AC</given-names></name>, <etal>et al</etal>
<article-title>VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2008</year>
<month>9</month>;<volume>64</volume>(<issue>9</issue>):<fpage>889</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-008-0507-5</pub-id>
<?supplied-pmid 18542936?><pub-id pub-id-type="pmid">18542936</pub-id></mixed-citation></ref><ref id="pone.0168732.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Yildirim</surname><given-names>E</given-names></name>, <name><surname>Erol</surname><given-names>K</given-names></name>, <name><surname>Birdane</surname><given-names>A</given-names></name>. <article-title>Warfarin dose requirement in Turkish patients: The influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII</article-title>. <source>Hippokratia</source>. [Article]. <year>2014</year>;<volume>18</volume>(<issue>4</issue>):<fpage>319</fpage>&#x02013;<lpage>27</lpage>. <?supplied-pmid 26052198?><pub-id pub-id-type="pmid">26052198</pub-id></mixed-citation></ref><ref id="pone.0168732.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Ozer</surname><given-names>N</given-names></name>, <name><surname>Cam</surname><given-names>N</given-names></name>, <name><surname>Tangurek</surname><given-names>B</given-names></name>, <name><surname>Ozer</surname><given-names>S</given-names></name>, <name><surname>Uyarel</surname><given-names>H</given-names></name>, <name><surname>Oz</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population</article-title>. <source>Heart and Vessels</source>. [Article]. <year>2010</year>;<volume>25</volume>(<issue>2</issue>):<fpage>155</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1007/s00380-009-1177-7</pub-id>
<?supplied-pmid 20339978?><pub-id pub-id-type="pmid">20339978</pub-id></mixed-citation></ref><ref id="pone.0168732.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Luis</surname><given-names>JR</given-names></name>, <name><surname>Rowold</surname><given-names>DJ</given-names></name>, <name><surname>Regueiro</surname><given-names>M</given-names></name>, <name><surname>Caeiro</surname><given-names>B</given-names></name>, <name><surname>Cinnioglu</surname><given-names>C</given-names></name>, <name><surname>Roseman</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>The Levant versus the Horn of Africa: evidence for bidirectional corridors of human migrations</article-title>. <source>Am J Hum Genet</source>. <year>2004</year>
<month>3</month>;<volume>74</volume>(<issue>3</issue>):<fpage>532</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1086/382286</pub-id>
<?supplied-pmid 14973781?><pub-id pub-id-type="pmid">14973781</pub-id></mixed-citation></ref><ref id="pone.0168732.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Abu-Amero</surname><given-names>KK</given-names></name>, <name><surname>Gonzalez</surname><given-names>AM</given-names></name>, <name><surname>Larruga</surname><given-names>JM</given-names></name>, <name><surname>Bosley</surname><given-names>TM</given-names></name>, <name><surname>Cabrera</surname><given-names>VM</given-names></name>. <article-title>Eurasian and African mitochondrial DNA influences in the Saudi Arabian population</article-title>. <source>BMC Evol Biol</source>. <year>2007</year>;<volume>7</volume>:<fpage>32</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2148-7-32</pub-id>
<?supplied-pmid 17331239?><pub-id pub-id-type="pmid">17331239</pub-id></mixed-citation></ref><ref id="pone.0168732.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Zalloua</surname><given-names>PA</given-names></name>, <name><surname>Xue</surname><given-names>Y</given-names></name>, <name><surname>Khalife</surname><given-names>J</given-names></name>, <name><surname>Makhoul</surname><given-names>N</given-names></name>, <name><surname>Debiane</surname><given-names>L</given-names></name>, <name><surname>Platt</surname><given-names>DE</given-names></name>, <etal>et al</etal>
<article-title>Y-chromosomal diversity in Lebanon is structured by recent historical events</article-title>. <source>Am J Hum Genet</source>. <year>2008</year>
<month>4</month>;<volume>82</volume>(<issue>4</issue>):<fpage>873</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2008.01.020</pub-id>
<?supplied-pmid 18374297?><pub-id pub-id-type="pmid">18374297</pub-id></mixed-citation></ref><ref id="pone.0168732.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Behar</surname><given-names>DM</given-names></name>, <name><surname>Villems</surname><given-names>R</given-names></name>, <name><surname>Soodyall</surname><given-names>H</given-names></name>, <name><surname>Blue-Smith</surname><given-names>J</given-names></name>, <name><surname>Pereira</surname><given-names>L</given-names></name>, <name><surname>Metspalu</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>The dawn of human matrilineal diversity</article-title>. <source>Am J Hum Genet</source>. <year>2008</year>
<month>5</month>;<volume>82</volume>(<issue>5</issue>):<fpage>1130</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2008.04.002</pub-id>
<?supplied-pmid 18439549?><pub-id pub-id-type="pmid">18439549</pub-id></mixed-citation></ref><ref id="pone.0168732.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Zalloua</surname><given-names>PA</given-names></name>, <name><surname>Platt</surname><given-names>DE</given-names></name>, <name><surname>El Sibai</surname><given-names>M</given-names></name>, <name><surname>Khalife</surname><given-names>J</given-names></name>, <name><surname>Makhoul</surname><given-names>N</given-names></name>, <name><surname>Haber</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Identifying genetic traces of historical expansions: Phoenician footprints in the Mediterranean</article-title>. <source>Am J Hum Genet</source>. <year>2008</year>
<month>11</month>;<volume>83</volume>(<issue>5</issue>):<fpage>633</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2008.10.012</pub-id>
<?supplied-pmid 18976729?><pub-id pub-id-type="pmid">18976729</pub-id></mixed-citation></ref><ref id="pone.0168732.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Cadenas</surname><given-names>AM</given-names></name>, <name><surname>Zhivotovsky</surname><given-names>LA</given-names></name>, <name><surname>Cavalli-Sforza</surname><given-names>LL</given-names></name>, <name><surname>Underhill</surname><given-names>PA</given-names></name>, <name><surname>Herrera</surname><given-names>RJ</given-names></name>. <article-title>Y-chromosome diversity characterizes the Gulf of Oman</article-title>. <source>Eur J Hum Genet</source>. <year>2008</year>
<month>3</month>;<volume>16</volume>(<issue>3</issue>):<fpage>374</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejhg.5201934</pub-id>
<?supplied-pmid 17928816?><pub-id pub-id-type="pmid">17928816</pub-id></mixed-citation></ref><ref id="pone.0168732.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>AH</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name>, <name><surname>Smith</surname><given-names>A</given-names></name>, <name><surname>Haller</surname><given-names>C</given-names></name>, <name><surname>Drake</surname><given-names>K</given-names></name>, <name><surname>Linder</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations</article-title>. <source>Pharmacogenomics</source>. <year>2008</year>
<month>2</month>;<volume>9</volume>(<issue>2</issue>):<fpage>169</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.2217/14622416.9.2.169</pub-id>
<?supplied-pmid 18370846?><pub-id pub-id-type="pmid">18370846</pub-id></mixed-citation></ref><ref id="pone.0168732.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Cavallari</surname><given-names>LH</given-names></name>, <name><surname>Langaee</surname><given-names>TY</given-names></name>, <name><surname>Momary</surname><given-names>KM</given-names></name>, <name><surname>Shapiro</surname><given-names>NL</given-names></name>, <name><surname>Nutescu</surname><given-names>EA</given-names></name>, <name><surname>Coty</surname><given-names>WA</given-names></name>, <etal>et al</etal>
<article-title>Genetic and clinical predictors of warfarin dose requirements in African Americans</article-title>. <source>Clin Pharmacol Ther</source>. <year>2010</year>
<month>4</month>;<volume>87</volume>(<issue>4</issue>):<fpage>459</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2009.223</pub-id>
<?supplied-pmid 20072124?><pub-id pub-id-type="pmid">20072124</pub-id></mixed-citation></ref><ref id="pone.0168732.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Jeong</surname><given-names>H</given-names></name>, <name><surname>Takahashi</surname><given-names>H</given-names></name>, <name><surname>Drozda</surname><given-names>K</given-names></name>, <name><surname>Patel</surname><given-names>SR</given-names></name>, <name><surname>Shapiro</surname><given-names>NL</given-names></name>, <etal>et al</etal>
<article-title>Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism</article-title>. <source>Clin Pharmacol Ther</source>. <year>2012</year>
<month>4</month>;<volume>91</volume>(<issue>4</issue>):<fpage>660</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2011.269</pub-id>
<?supplied-pmid 22378156?><pub-id pub-id-type="pmid">22378156</pub-id></mixed-citation></ref><ref id="pone.0168732.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Cal</surname><given-names>S</given-names></name>, <name><surname>Peinado</surname><given-names>JR</given-names></name>, <name><surname>Llamazares</surname><given-names>M</given-names></name>, <name><surname>Quesada</surname><given-names>V</given-names></name>, <name><surname>Moncada-Pazos</surname><given-names>A</given-names></name>, <name><surname>Garabaya</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Identification and characterization of human polyserase-3, a novel protein with tandem serine-protease domains in the same polypeptide chain</article-title>. <source>BMC Biochem</source>. <year>2006</year>;<volume>7</volume>:<fpage>9</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2091-7-9</pub-id>
<?supplied-pmid 16566820?><pub-id pub-id-type="pmid">16566820</pub-id></mixed-citation></ref><ref id="pone.0168732.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>McDonald</surname><given-names>MG</given-names></name>, <name><surname>Rieder</surname><given-names>MJ</given-names></name>, <name><surname>Nakano</surname><given-names>M</given-names></name>, <name><surname>Hsia</surname><given-names>CK</given-names></name>, <name><surname>Rettie</surname><given-names>AE</given-names></name>. <article-title>CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant</article-title>. <source>Mol Pharmacol</source>. <year>2009</year>
<month>6</month>;<volume>75</volume>(<issue>6</issue>):<fpage>1337</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1124/mol.109.054833</pub-id>
<?supplied-pmid 19297519?><pub-id pub-id-type="pmid">19297519</pub-id></mixed-citation></ref><ref id="pone.0168732.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Caldwell</surname><given-names>MD</given-names></name>, <name><surname>Awad</surname><given-names>T</given-names></name>, <name><surname>Johnson</surname><given-names>JA</given-names></name>, <name><surname>Gage</surname><given-names>BF</given-names></name>, <name><surname>Falkowski</surname><given-names>M</given-names></name>, <name><surname>Gardina</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>CYP4F2 genetic variant alters required warfarin dose</article-title>. <source>Blood</source>. <year>2008</year>
<month>4</month>
<day>15</day>;<volume>111</volume>(<issue>8</issue>):<fpage>4106</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2007-11-122010</pub-id>
<?supplied-pmid 18250228?><pub-id pub-id-type="pmid">18250228</pub-id></mixed-citation></ref><ref id="pone.0168732.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Voora</surname><given-names>D</given-names></name>, <name><surname>Koboldt</surname><given-names>DC</given-names></name>, <name><surname>King</surname><given-names>CR</given-names></name>, <name><surname>Lenzini</surname><given-names>PA</given-names></name>, <name><surname>Eby</surname><given-names>CS</given-names></name>, <name><surname>Porche-Sorbet</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans</article-title>. <source>Clin Pharmacol Ther</source>. <year>2010</year>
<month>4</month>;<volume>87</volume>(<issue>4</issue>):<fpage>445</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2009.291</pub-id>
<?supplied-pmid 20200517?><pub-id pub-id-type="pmid">20200517</pub-id></mixed-citation></ref><ref id="pone.0168732.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Caulfield</surname><given-names>T</given-names></name>, <name><surname>Fullerton</surname><given-names>SM</given-names></name>, <name><surname>Ali-Khan</surname><given-names>SE</given-names></name>, <name><surname>Arbour</surname><given-names>L</given-names></name>, <name><surname>Burchard</surname><given-names>EG</given-names></name>, <name><surname>Cooper</surname><given-names>RS</given-names></name>, <etal>et al</etal>
<article-title>Race and ancestry in biomedical research: exploring the challenges</article-title>. <source>Genome Med</source>. <year>2009</year>;<volume>1</volume>(<issue>1</issue>):<fpage>8</fpage>
<pub-id pub-id-type="doi">10.1186/gm8</pub-id>
<?supplied-pmid 19348695?><pub-id pub-id-type="pmid">19348695</pub-id></mixed-citation></ref></ref-list></back></article>